David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)
December 13, 2022 03:37 PM EST
Financing
Pharma

Eli Lil­ly an­tic­i­pates rev­enue boost in 2023 as it pre­pares to launch slate of new drugs

Tyler Patchen

News Reporter

Eli Lil­ly ex­ec­u­tives are bull­ish on its prospects for next year as the In­di­anapo­lis phar­ma lifts the cov­er on its 2023 fi­nan­cial guid­ance.

Rev­enues are …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times